<DOC>
	<DOCNO>NCT01366001</DOCNO>
	<brief_summary>The purpose study assess safety tolerability ALKS33-BUP administer opioid-experienced cocaine abuser .</brief_summary>
	<brief_title>ALK33BUP-101 : Safety Pharmacodynamic Effects ALKS 33-BUP Administered Alone When Co-administered With Cocaine</brief_title>
	<detailed_description>There currently available pharmacologic treatment cocaine abuse and/or dependence unmet medical need grow . In collaboration National Institute Drug Abuse ( NIDA ) , Alkermes , Inc. investigate fixed-dose combination product consist ALKS 33 ( also refer RDC-0313 ) buprenorphine ( ALKS 33-BUP ) treatment cocaine abuse and/or dependence ( Grant Number R01DA031000 ) . This randomized , double-blind , placebo-controlled , parallel design inpatient study . Eligibility establish include response cocaine infusion baseline , prior study drug administration . Approximately 30 opioid-experienced cocaine abuser randomize 1:1:1 receive study drug . Study drug administer daily 10 consecutive day . Pharmacodynamic assessment drug-drug interaction closely monitor study . Following study drug administration , subject receive cocaine infusion evaluate effect treatment subjective effect PK/PD cocaine . Subjects discharge clinical research unit 2 day last infusion cocaine . Subjects return follow-up 7 14 day discharge . The full study take subject approximately 28 day , 17 day inpatient stay .</detailed_description>
	<mesh_term>Cocaine-Related Disorders</mesh_term>
	<mesh_term>ALKS-33</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<mesh_term>Cocaine</mesh_term>
	<criteria>Inclusion Criteria In order participate study , subject must : 1 . Be volunteer seek treatment drug addiction . 2 . Be 21 50 year age , inclusive . 3 . Have body mass index ( BMI ) within range 18.0 30.0 kilogram per square meter ( kg/m2 ) , inclusive , minimum weight least 50.0 kilogram ( kg ) screening . 4 . Have experience use cocaine smoke IV route within past year , positive urinary drug screen cocaine prior study intake . 5 . Have opioid experience within 3 year , physically dependent opioids confirm naloxone challenge . 6 . Be able verbalize understanding consent form , able provide write informed consent , verbalize willingness complete study procedure , prior initiation protocolspecific procedure . 7 . Have medical history physical examination demonstrate clinically significant contraindication participate study . 8 . Pass qualification criterion response IV cocaine infusion . Exclusion Criteria In order participate study , subject must : 1 . Have current past history seizure disorder , include alcohol stimulantrelated seizure , febrile seizure , significant family history idiopathic seizure disorder . Have previous clinically significant reaction cocaine , include loss consciousness seizure . 2 . Other drug abuse , history clinically significant major psychiatric illness ( eg , severe mood disorder , psychotic disorder ) accord Diagnostic Statistical Manual , Fourth Edition , Text Revision ( DSM IVTR ) criterion disorder secondary drug use opinion investigator . 3 . Present symptom withdrawal follow administration naloxone challenge test . 4 . Have history liver disease current elevation aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) exceed 3x upper limit normal . 5 . Have history allergy hypersensitivity opioid agonist ( eg , buprenorphine ) opioid antagonist ( eg , naltrexone , naloxone ) . 6 . Have history hepatitis C , human immunodeficiency virus ( HIV ) type 1 and/or 2 . 7 . Have positive urine drug screen upon screen drug cocaine ( bioequivalent metabolite ) , marijuana ( tetrahydrocannabinol , THC ) , due longelimination halflife , benzodiazepine . 8 . Have positive alcohol test screen admission inpatient phase study . If subject present positive alcohol test , subject reschedule discretion sponsor investigator designee . 9 . If female , currently pregnant lactate plan become pregnant within 60 day last study drug administration . 10 . Have clinically significant history cardiac disease , include cardiovascular conduction abnormality electrocardiogram ( ECG ) evidence cardiac abnormality . 11 . Have use cocaine exclusively intranasal route .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Opioid</keyword>
	<keyword>Cocaine</keyword>
	<keyword>Dependence</keyword>
	<keyword>Abuse</keyword>
	<keyword>Intravenous</keyword>
	<keyword>Buprenorphine</keyword>
</DOC>